The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Outpatient Treatment of Recent-Onset Atrial Fibrillation with the “Pill-in-the-Pocket” Approach
Open accessAbstract
BACKGROUND: In-hospital administration of flecainide and propafenone in a single oral loading dose has been shown to be effective and superior to placebo in terminating atrial fibrillation. We evaluated the feasibility and the safety of self-administered oral loading of flecainide and propafenone in terminating atrial fibrillation of recent onset outside the hospital. METHODS: We administered either flecainide or propafenone orally to restore sinus rhythm in 268 patients with mild heart disease or none who came to the emergency room with atrial fibrillation of recent onset that was hemodynamically well tolerated. Of these patients, 58 (22 percent) were excluded from the study because of treatment failure or side effects. Out-of-hospital self-administration of flecainide or propafenone--the "pill-in-the-pocket" approach--after the onset of heart palpitations was evaluated in the remaining 210 patients (mean age [+/-SD], 59+/-11 years). RESULTS: During a mean follow-up of 15+/-5 months, 165 patients (79 percent) had a total of 618 episodes of arrhythmia; of those episodes, 569 (92 percent) were treated 36+/-93 minutes after the onset of symptoms. Treatment was successful in 534 episodes (94 percent); the time to resolution of symptoms was 113+/-84 minutes. Among the 165 patients with recurrences, the drug was effective during all the arrhythmic episodes in 139 patients (84 percent). Adverse effects were reported during one or more arrhythmic episodes by 12 patients (7 percent), including atrial flutter at a rapid ventricular rate in 1 patient and noncardiac side effects in 11 patients. The numbers of monthly visits to the emergency room and hospitalizations were significantly lower during follow-up than during the year before the target episode (P<0.001 for both comparisons). CONCLUSIONS: In a selected, risk-stratified population of patients with recurrent atrial fibrillation, pill-in-the-pocket treatment is feasible and safe, with a high rate of compliance by patients, a low rate of adverse events, and a marked reduction in emergency room visits and hospital admissions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An alternative to emergency department treatment for patients with infrequent but disabling AF is the”
From 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry (2017) · cites this paper as Alboni et al., 2004
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.
Haïssaguerre, M., Jaïs, P., Shah, D. C., Takahashi, A., Hocini, M., Quiniou, G., Garrigue, S., Mouroux, A. L., Métayer, P. L., & Clémenty, J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809033391003 · Cited by 8,040
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505
A comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405
Gelder, I. C. V., Hagens, V. E., Bosker, H. A., Kingma, J. H., Otto Kamp, B., Kingma, T., Said, S. A., Darmanata, J. I., Timmermans, A. J. M., Tijssen, J. G. P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021375 · Cited by 2,355
Hohnloser, S. H., Kück, K., & Lilienthal, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03230-x · Cited by 1,132
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation
CARLSSON, J., Miketíc, S., Windeler, J., Cuneo, A., Haun, S., Micus, S., Walter, S., & Tebbe, U. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00332-2 · Cited by 938
Capucci, A., Lenzi, T., Boriani, G., Trisolino, G., Binetti, N., Cavazza, M., Fontana, G. A., & Magnani, B. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91392-h · Cited by 227
Capucci, A., Boriani, G., Botto, G. L., Lenzi, T., Rubino, I., Falcone, C., Trisolino, G., Casa, S. D., Binetti, N., Cavazza, M., et al. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90915-6 · Cited by 172
Self-citationBoriani, G., Biffi, M., Capucci, A., Botto, G. L., Broffoni, T., Rubino, I., Casa, S. D., Sanguinetti, M., & Magnani, B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-8-199704150-00006 · Cited by 171
Self-citationKhan, I. A. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01116-5 · Cited by 145
Flagged first, then by citations
Research works printed but not linked: 1
- Villani GQ, 1990, G Ital Cardiol, 20, 564
Cited by
Sorted by citations
Items 201–300 of 478
Acute Management of Atrial Fibrillation
Beck, H., & See, V. Y. (2012) · Cardiology Clinics · doi:10.1016/j.ccl.2012.07.007 · Cited by 11
Costantino, G., Podda, G. M., Falsetti, L., Iannone, P., Lages, A., Marra, A. M., Masala, M. S., Reiakvam, O. M., Savva, F., Schovánek, J., et al. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1580-x · Cited by 10
Drug Therapy for Atrial Fibrillation
Musco, S., Conway, E. L., & Kowey, P. R. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.08.002 · Cited by 10
Treatment of atrial fibrillation
Blaauw, Y., & Crijns, H. J. G. M. (2008) · Heart · doi:10.1136/hrt.2005.079020 · Cited by 11
The “Pill-in-the-Pocket” Approach to Atrial Fibrillation
Grönefeld, G. C., & Hohnloser, S. H. (2005) · New England Journal of Medicine · doi:10.1056/nejm200503173521119 · Cited by 10
Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation
Compagnucci, P., Guerra, F., & Capucci, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1906729 · Cited by 10
Pharmakotherapie der supraventrikulären Rhythmusstörungen
Lewalter, T., & Nickenig, G. (2005) · Der Internist · doi:10.1007/s00108-005-1544-0 · Cited by 10
Vinson, D. R., Rauchwerger, A. S., Karadi, C. A., Shan, J., Warton, E. M., Zhang, J. Y., Ballard, D. W., Mark, D. G., Hofmann, E. R., Cotton, D. M., et al. (2023) · Trials · doi:10.1186/s13063-023-07230-2 · Cited by 10
Atrial Fibrillation in Singapore and Malaysia: Current Trends and Future Prospects
Omar, R., Teo, W. S., Foo, D. C. G., Han, C. K., Jamaluddin, A. N., Low, L. P., & Ong, T. K. (2011) · Journal of Arrhythmia · doi:10.1016/s1880-4276(11)80042-6 · Cited by 9
The pathophysiology and management of atrial fibrillation
Banner, D. (2008) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2008.3.5.29332 · Cited by 9
Atrial Fibrillation: Antiarrhythmic Therapy
Psotka, M. A., & Lee, B. K. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.07.004 · Cited by 9
Pharmacological Management of Atrial Fibrillation: One, None, One Hundred Thousand
Lucà, F., Meir, M. L., Rao, C. M., Parise, O., Vasquez, L., Carella, R., Lorusso, R., Daniela, B., Maessen, J. G., Gensini, G. F., et al. (2011) · Cardiology Research and Practice · doi:10.4061/2011/874802 · Cited by 9
“Finally, patients should be instructed to take flecainide or propafenone when symptoms of AF occur [35].”
BackgroundBuccelletti, F., Somma, S. D., Iacomini, P., Galante, A., Pugliese, F. R., Alegiani, F., Bertazzoni, G., Marsiliani, D., Carroccia, A., Granato, A., et al. (2013) · PubMed · Cited by 9
Pharmacological Therapy for Rate and Rhythm Control for Atrial Fibrillation in 2017
Kanagaratnam, L. B., Kowey, P. R., & Whalley, D. W. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.05.134 · Cited by 10
Atrial Fibrillation: Goals of Therapy and Management Strategies to Achieve the Goals
Padanilam, B. J., & Prystowsky, E. N. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.08.006 · Cited by 9
Atrial fibrillation: Choosing an antiarrhythmic drug
Rudo, T. J., & Kowey, P. R. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0077-z · Cited by 9
“A recent study of this “pill-in-the-pocket” approach suggests that it may be used safely in a select group of outpatients previously shown to tolerate the drug in a monitored setting [ 21 ].”
BackgroundUpdate on medical management of atrial fibrillation in the modern era
Gopinathannair, R., Sullivan, R. M., & Olshansky, B. (2009) · Heart Rhythm · doi:10.1016/j.hrthm.2009.02.013 · Cited by 8
Boriani, G., Biffi, M., Diemberger, I., Domenichini, G., Marziali, A., & Martignani, C. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.028 · Cited by 9
Lacoste, J. L., Szymanski, T. W., Avalon, J. C., Kabulski, G. M., Kohli, U., Marrouche, N. F., Singla, A., Balla, S., & Jahangir, A. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00529-6 · Cited by 8
“Hemodynamically unstable patients with AF and rapid ventricular rate response should undergo emergent synchronized direct-current cardioversion to restore NSR [31].”
MethodInfluentialLimantoro, I., de Vos, C. B., Delhaas, T., Marcos, E. G., Blaauw, Y., Weijs, B., Tieleman, R. G., Pisters, R., Schotten, U., Gelder, I. C. V., et al. (2013) · Heart Rhythm · doi:10.1016/j.hrthm.2013.12.010 · Cited by 8
Inhibition of voltage-gated Na+ currents by eleclazine in rat atrial and ventricular myocytes
Caves, R. E., Carpenter, A., Choisy, S. C. M., Clennell, B., Cheng, H., McNiff, C., Mann, B., Milnes, J. T., Hancox, J. C., & James, A. F. (2020) · Heart Rhythm O2 · doi:10.1016/j.hroo.2020.05.006 · Cited by 8
Is amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation?
Barra, S., Primo, J. J., Gonçalves, H., Bovéda, S., Providencia, R. A., & Grace, A. A. (2022) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2021.03.019 · Cited by 8
Drug Therapy for Atrial Fibrillation
Conway, E. L., Musco, S., & Kowey, P. R. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.10.003 · Cited by 8
The worldwide social burden of atrial fibrillation: What should be done and where do we go?
Santini, M., & Ricci, R. P. (2006) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/pl00021934 · Cited by 8
Management of atrial fibrillation and concomitant coronary artery disease
Martin, R. I. R., & Bates, M. G. D. (2017) · Continuing Cardiology Education · doi:10.1002/cce2.55 · Cited by 8
Do we need pharmacological therapy for atrial fibrillation in the ablation era?
Lévy, S. (2006) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-006-9075-8 · Cited by 8
“More recently, Alboni et al. [ 20 ] have shown that the “pill-in-the-pocket” approach in a selected group of patients is efficient, as 94% of episodes in 165 patients were successfully terminated and safe as only 1 patient developed atrial flutter with rapid ventricular conduction and 11 non-cardiac side effects were…”
BackgroundAtrial Fibrillation in Elite Athletes: A Comprehensive Review of the Literature
Kourek, C., Briasoulis, A., Tsougos, E., & Paraskevaidis, I. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11100315 · Cited by 7
“Class I antiarrhythmics could be used as a ‘pill-in-the-pocket’ approach in patients with sporadic AF [87].”
MethodKukendrarajah, K., Ahmad, M., Carrington, M., Ioannou, A., Taylor, J., Razvi, Y., Παπαγεωργίου, Ν., Mead, G. E., Nevis, I., D’Ascenzo, F., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013255.pub2 · Cited by 8
Sp, G., Панченко, Е. П., Mironov, N. Y., Михайловна, Б. М., Gagloeva, D. A., Elfimova, E. M., Станиславовна, К. Е., Laiovich, L. I., Litvin, A. Y., Maykov, E. B., et al. (2025) · Eurasian heart journal · doi:10.38109/2225-1685-2025-3-6-77 · Cited by 8
Przybylski, R., Eberly, L. M., Alexander, M. E., Bezzerides, V. J., DeWitt, E. S., Dionne, A., Mah, D. Y., Triedman, J. K., Walsh, E. P., & O’Leary, E. T. (2023) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16095 · Cited by 7
“8,19 Neither event required intervention and overall, the adverse event rate in our cohort was similar to that reported in typical adult populations at 4% of total episodes.”
ResultDie Behandlung von Vorhofflimmern im Alltag
Meinertz, T., & Willems, S. (2008) · Der Internist · doi:10.1007/s00108-008-2152-6 · Cited by 7
Diagnosis and Management of Atrial Fibrillation: An Overview
Romero, I., Nedios, S., & Kriatselis, C. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12090 · Cited by 7
Overview of pathophysiology and management of AF
Banner, D., & Lauck, S. (2013) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2013.8.5.241 · Cited by 7
Contemporary Approach to Electrical and Pharmacological Cardioversion of Atrial Fibrillation
Rajagopalan, B., & Curtis, A. B. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2610 · Cited by 7
de Antonio, V. Z., Silva, A. C., Stocco, F. G., Silva, B. A., Marum, A. A., Bortolotto, A. L., Belardinelli, L., & Verrier, R. L. (2018) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.13708 · Cited by 7
“However, oral delivery of agents that have been tested, including flecainide, propafenone, and ranolazine, is associated with a relatively long latency of effect, in the range of hours.(1,2,4,6) This important limitation has stimulated interest in an alternative approach to self‐administration out‐of‐hospital, notably…”
BackgroundNormal Quality of Life after the Cox-Maze Procedure for Atrial Fibrillation
Melby, S. J., Zierer, A. F., Lubahn, J. G., Bailey, M. S., Cox, J. L., Schuessler, R. B., & Damiano, R. J. (2008) · Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery · doi:10.1097/imi.0b013e31819165d7 · Cited by 7
Ranolazine Versus Amiodarone for Prevention of Postoperative Atrial Fibrillation
Burashnikov, A., & Antzelevitch, C. N. (2011) · Future Cardiology · doi:10.2217/fca.11.67 · Cited by 7
Goldman, M. E., & Croft, L. B. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.016 · Cited by 7
Li, L., Ruan, Y., Liu, N., Zhao, Q., Zhang, M., Li, X., Zuo, S., Jiang, L., Wu, K., Bai, R., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00353 · Cited by 6
“, 2016) This approach resolves the symptoms within 2–3 h and significantly decreases the visits to the emergency room and hospitalizations, while major adverse effects have been reported, including significant QRS wave widening, atrial flutter at a rapid ventricular rate, Brugada syndrome (BrS) ECG pattern, and sinus…”
BackgroundChinese Guidelines for the Diagnosis and Management of Atrial Fibrillation
Chinese Society of Cardiology, C. M. A., & Heart Rhythm Committee of Chinese Society of Biomedical Engineering (2024) · Cardiology Discovery · doi:10.1097/cd9.0000000000000123 · Cited by 7
Endurance Sports and Atrial Fibrillation: A Puzzling Conundrum
Ostojic, M., Ostojić, M., Petrović, O., Nedeljkovic‐Arsenovic, O., Perone, F., Banović, M., Stojmenović, T., Stojmenovič, D., Giga, V. L., Beleslin, B., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247691 · Cited by 10
“For athletes with clinically significant symptoms during exercise or at rest, efforts should be made to maintain normal sinus rhythm, typically through a trial of an antiar-rhythmic agent, which can be very complicated [68,69].”
Medical management of atrial fibrillation
Hersi, A. S., & Wyse, D. G. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0070-6 · Cited by 6
“As noted above, pharmacologic cardioversion works best when drug is administered shortly after the onset of AF [ 23 ].”
BackgroundDoki, K., Sekiguchi, Y., Kuga, K., Aonuma, K., & Homma, M. (2016) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000239 · Cited by 6
Monitoring Atrial Fibrillation After Catheter Ablation.
Forleo, G. B., Casella, M., Russo, A. D., Moltrasio, M., Fassini, G., Tesauro, M., & Tondo, C. (2014) · PubMed Central · doi:10.4022/jafib.1040 · Cited by 6
Roden, D. M., Darbar, D., & Kannankeril, P. J. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_102 · Cited by 6
Haro, L. H., Hess, E. P., & Decker, W. W. (2006) · Medical Clinics of North America · doi:10.1016/j.mcna.2005.12.004 · Cited by 6
“Young patients who have normal or near normal hearts and a history of recurrent paroxysmal AF (PAF) have been treated in Italy with a ‘‘pill in the pocket approach’’ [17].”
BackgroundVincenti, A., Rota, M., Spinelli, M., Corciulo, M., Ceglia, S. D., Rovaris, G., Antolini, L., & Genovesi, S. (2011) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2011.08.005 · Cited by 6
Current Role of Medical Therapy for Prevention or Termination of Atrial Fibrillation
Baranchuk, A. M., Morillo, C. A., Thoenes, M., Ventura, R., & Connolly, S. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-163-5_13 · Cited by 6
Elektrische und pharmakologische Frühkardioversion von Vorhofflimmern
Linhart, M., & Lewalter, T. (2006) · Herzschrittmachertherapie + Elektrophysiologie · doi:10.1007/s00399-006-0514-0 · Cited by 7
Ibutilide revisited: stronger and safer than ever
Gopinathannair, R., & Olshansky, B. (2008) · EP Europace · doi:10.1093/europace/eun337 · Cited by 6
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.02.001 · Cited by 14
Narrow complex (supraventricular) tachycardias
Linton, N., & Dubrey, S. W. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2009.080101 · Cited by 5
“A more recent approach is the use of the “pill in the pocket” method, in which a patient uses a pre-planned prescription of flecainide or propafenone, for example, to terminate recent onset atrial fibrillation.”
MethodTiming of cardioversion in atrial fibrillation: the sooner the better?
Capranzano, P., & Calvi, V. I. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa132 · Cited by 5
Reißmann, B., BREITHARDT, G. E., Camm, A. J., Gelder, I. C. V., Metzner, A., & Kirchhof, P. F. (2021) · EP Europace · doi:10.1093/europace/euab023 · Cited by 5
Pharmacological cardioversion of atrial fibrillation: practical considerations
Wybraniec, M. T., Kampka, Z., & Mizia‐Stec, K. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16547 · Cited by 6
Hauguel‐Moreau, M., Guedeney, P., Dauphin, C., Auffret, V., Marijon, É., Aldebert, P., Clerc, J.-M., Beygui, F., Elbaz, M., Khalil, W. A., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad100 · Cited by 5
Rienstra, M., Silva, A. C., Kuijper, A. F. M., Eijsbouts, S. C. M., Kraaier, K., Janota, T., van Ofwegen-Hanekamp, C. E. E., Tuininga, Y. S., Badings, E., Merino, J. L., et al. (2025) · EP Europace · doi:10.1093/europace/euaf064 · Cited by 5
Evaluation of Children With Palpitations
Rivera, R. F., Chambers, P., & Ceresnak, S. R. (2011) · Clinical Pediatric Emergency Medicine · doi:10.1016/j.cpem.2011.09.002 · Cited by 5
Antiarrhythmic Drug Therapy in the Treatment of Acute and Chronic Atrial Flutter
Amadori, M., Rapacciuolo, A., & Diemberger, I. (2022) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2022.05.006 · Cited by 5
Burashnikov, A., & Antzelevitch, C. N. (2023) · Heart Rhythm · doi:10.1016/j.hrthm.2023.05.005 · Cited by 5
Electrical and Pharmacologic Cardioversion for Atrial Fibrillation
Kim, S. S., & Knight, B. P. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.08.003 · Cited by 5
Antiarrhythmic drugs for atrial fibrillation
Marinelli, A., & Capucci, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.554400 · Cited by 5
“This may be suitable for patients with recurrent episodes of highly symptomatic AF, and in this selected population was found to improve QoL and to decrease hospital admissions [96].”
BackgroundMorais, J., Osterspey, A., Tamargo, J. L., Zamorano, L., Despres, C., Dickstein, K., Lekakis, J. P., McGregor, K., Metra, M., Budaj, A., et al. (2006) · Cited by 5
Atrial Fibrillation: A Historical Perspective
Khasnis, A. A., & Thakur, R. K. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.08.001 · Cited by 5
Stiell, I. G., Taljaard, M., Eagles, D. A., Yadav, K., Vadeboncœur, A., Hohl, C. M., Archambault, P. M., Birnie, D. H., Brown, E. L., Campbell, S., et al. (2025) · BMJ · doi:10.1136/bmj-2025-085632 · Cited by 4
Kozieł, M., Mihajlovic, M., Nedeljkovic, M. A., Pavlović, N., Paparisto, V., Musić, L., Trendafilova, E., Dan, A. R., Kušljugić, Z., Dan, G., et al. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14080 · Cited by 4
“Propafenone is well tolerated, safe and effective in patients with recurrent AF [44].”
BackgroundAtrial fibrillation management: evaluating rate vs rhythm control
Nguyen, T. L., Jolly, U. S., Sidhu, K., Yee, R. K., & Leong‐Sit, P. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1164033 · Cited by 4
“safe, feasible, and efficacious in patients without structural heart disease [50].”
BackgroundClinical Pearls in Using Antiarrhythmic Drugs in the Outpatient Setting
Parker, M. H., & Sanoski, C. A. (2015) · Journal of Pharmacy Practice · doi:10.1177/1933719115615878 · Cited by 4
Riad, F. S., & Waldo, A. L. (2019) · Journal of Innovations in Cardiac Rhythm Management · doi:10.19102/icrm.2019.101005 · Cited by 4
Strategies for Rhythm Control in Atrial Fibrillation
Narayanan, K. (2020) · Indian Journal of Clinical Cardiology · doi:10.1177/2632463620936018 · Cited by 4
Development of a Care Pathway for Atrial Fibrillation Patients in the Emergency Department
Do, D. H., Bernardes‐Souza, B., Merjanian, M., Lombardo, B., Donaldson, D. M., McCullough, L. B., Boyle, N. G., & Cooper, R. J. (2022) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000289 · Cited by 4
“Based on published data, we selected oral propafenone, 41–43 oral fle-cainide, 41–44 or intravenous procainamide 40 for chemical cardiover-sion in the ED, as the conversion rates of these 3 agents is higher than the rates reported for dofetilide, 45 ibutilide, 46 or amiodarone.”
Non-investigational antiarrhythmic drugs: long-term use and limitations
Gjesdal, K. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902927647 · Cited by 4
“For safety reasons guidelines consider self-administration of flecainide or amiodarone a Class IIa recommendation, after an initial trial in hospital [73].”
BackgroundEvaluation and Management of the Atrial Fibrillation Patient
Steinberg, B. A., Beckley, P. D., Deering, T. F., Clark, C. L., Amin, A., Bauer, K. A., Cryer, B., MANSOUR, M. C., Scheiman, J. M., Zenati, M. A., et al. (2013) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0b013e31829834ed · Cited by 4
Atrial Fibrillation in Congestive Heart Failure: Current Management
Boyle, N. G., & Shivkumar, K. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.09.016 · Cited by 4
Atrial fibrillation: Pathophysiology and current therapy
Miyazaki, S., Shah, A. J., Scherr, D., & Haı̈ssaguerre, M. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.554426 · Cited by 4
“In order to implement the ‘ pill-in-the-pocket ’ technique, the effi cacy and safety of oral treatment should be tested in hospital (45).”
MethodAlbakri, A., & Klingenheben, T. (2017) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2017.07.003 · Cited by 4
Management of Patients with Atrial Fibrillation: Focus on Treatment Options
Matusik, P. T., Lelakowski, J., Małecka, B., Bednarek, J., & Noworolski, R. (2016) · Journal of Atrial Fibrillation · doi:10.4022/jafib.1450 · Cited by 4
Antiarrhythmic drugs part 2: rhythm-control drugs
Sampson, M. G. (2019) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2019.0067 · Cited by 4
Christ, T., & Ravens, U. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.09.013 · Cited by 4
“Here, flecainide, or propafenone, was shown to be not only highly effective for conversion but also safe [ 11 ].”
BackgroundCapucci, A. (2022) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2022.11.001 · Cited by 4
Management Strategies in Atrial Fibrillation in Patients With Heart Failure
Shaikh, A. Y., Maan, A., Heist, E. K., Tighe, D. A., Aurigemma, G. P., & McManus, D. D. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e31825dcf9b · Cited by 3
“These drugs also are effective in the long-term maintenance of sinus rhythm, often used as a “pill-in-the-pocket” approach.(60,61) The Cardiac Arrhythmia Suppression Trial, which involved administration of encainide or flecainide for the suppression of ventricular ectopy after myocardial infarction, showed an increase…”
BackgroundLiberman, L., Starc, T. J., & Silver, E. S. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.03.001 · Cited by 3
Kang, K., Shim, J., Ahn, J., Lee, D. I., Kim, J., Joung, B., & Choi, K. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.140 · Cited by 3
“플레카이니드와 프로파페논은 발작성 심방 세동뿐만 아니라[39,76], 지속성 심방세동 환자에서도 심방”
Symptom/Rhythm Correlation With Patient Owned Device: Insights Into Practice And Challenges.
Shurrab, M., Langer, A., Crystal, E., & Newman, D. M. (2016) · PubMed Central · doi:10.4022/jafib.1390 · Cited by 3
Restrepo-Jaramillo, C. A. (2016) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2016.10.008 · Cited by 3
How to: Antiarrhythmika in der klinischen Anwendung
Hillmann, H. A. K., Betz, K., Linz, D., & Duncker, D. (2023) · Herzschrittmachertherapie + Elektrophysiologie · doi:10.1007/s00399-022-00919-y · Cited by 3
Flecainide toxicity with pill-in-pocket approach from accidental overdose: a case report
Oudih, M. A., Ginsburg, A., Hakim, M., Zou, F., & Guttenplan, N. A. (2024) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytae522 · Cited by 3
“8 However, flecainide toxicity is life-threatening.”
Frequenz- und Rhythmuskontrolle bei Vorhofflimmern
Weipert, K. F., Erkapic, D., & Schmitt, J. (2015) · Herz · doi:10.1007/s00059-014-4201-3 · Cited by 3
Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline?
Rajagopalan, B., & Curtis, A. B. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1022495 · Cited by 3
“Flecainide and propafenone can also be used in a “pill-in-the-pocket approach” for paroxysmal AF; it is recommended that initial administration be in a controlled environment under observation [43].”
BackgroundAtrial fibrillation: Challenges and opportunities
Hersi, A. S., Mitchell, L. B., & Wyse, D. G. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70998-9 · Cited by 3
“propafenone, and were then followed as outpatients (38).”
BackgroundDiagnostic Evaluation and Follow-Up of Patients with Atrial Fibrillation
Dillon, P., & Ghanbari, H. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.07.008 · Cited by 3
Lakdawalla, D. N., Turakhia, M. P., Jhaveri, M., Mozaffari, E., Davis, P., Bradley, L. A., & Solomon, M. D. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.19 · Cited by 3
Atrial fibrillation in emergency department: prevalence of sinus rhythm 1 week after discharge
Fundarò, C., Galli, A., Paglia, S., Colombo, S., Rovellini, A., Colombo, L., Monzani, V., Coen, D., & Guzzetti, S. (2011) · Emergency Medicine Journal · doi:10.1136/emj.2010.107581 · Cited by 3
“Exclusion criteria were: (1) patients admitted to hospital; (2) no indication for rhythm control in accordance with the recommendations of international guidelines (mostly permanent AF); (3) haemodynamic instability (defined as systolic arterial pressure #90 mm Hg); (4) heart failure New York Heart Association (NYHA)…”
BackgroundManagement of atrial fi brillation
Lip, G. Y. H., & Tse, H. (2007) · Cited by 3
Antiarrhythmic Agent Induced Ventricular Tachycardia
Agrawal, Y., Kalavakunta, J. K., & Gupta, V. A. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000483 · Cited by 3
Anti-arrhythmic therapy in athletes
Zorzi, A., Cipriani, A., & Corrado, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.027 · Cited by 3
Flecainide-Associated Cardiogenic Shock in a Patient with Atrial Fibrillation
Gjermeni, E., Bollmann, A., Hindricks, G., & Müssigbrodt, A. (2019) · Case Reports in Cardiology · doi:10.1155/2019/4820652 · Cited by 3
“Flecainide proved to be safe and effective as “pill-in-thepocket” treatment strategy with a single oral dose of 200– 300mg for termination of recent-onset (<48 h) AF [3].”
BackgroundMethodPharmacologic and Nonpharmacologic Management of Atrial Fibrillation
Dahya, V., & Taigen, T. L. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2019.04.004 · Cited by 3
Temas de actualidad 2005: electrofisiología y arritmias
Lozano, I. F., & Merino, J. L. (2006) · Revista Española de Cardiología · doi:10.1157/13084445 · Cited by 3
Utility of adjunctive single oral bolus propafenone therapy in patients with atrial defibrillators
SCHWARTZMAN, D. S., Harvey, M. N., HOYT, R. H., Koehler, J. L., Ujhelyi, M. R., & Euler, D. E. (2006) · EP Europace · doi:10.1093/europace/euj051 · Cited by 3
Metadata
- Authors
- Alboni, P., Botto, G. L., Baldi, N., Luzi, M., Russo, V., Gianfranchi, L., Marchi, P., Calzolari, M., Solano, A., Baroffio, R., & Gaggioli, G.
- Affiliations
- Ospedale Sant'Anna (IT)
- Ospedale SS. Annunziata (IT)
- Santa Maria Nuova Hospital (IT)
- ORCID
- Botto, Giovanni L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-12-02
- Volume
- 351
- Issue
- 23
- Pages
- 2384-2391
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2026137049
- Cited by
- 479
- References
- 28
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 21 · 2020: 21 · 2019: 10 · 2018: 18 · 2017: 22 · 2016: 25 · 2015: 20 · 2014: 31 · 2013: 23 · 2012: 20
- FWCI
- 16.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- atrial fibrillation, flecainide, propafenone, oral loading dose, outpatient care, self-administration, sinus rhythm restoration, emergency department visits, hospitalization reduction, adverse drug reactions, atrial flutter
- MeSH terms
- Administration, Oral, Ambulatory Care, Anti-Arrhythmia Agents, Atrial Fibrillation, Feasibility Studies, Female, Flecainide, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Propafenone, Prospective Studies, Self Administration, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
